Scratching the Surface: NECTIN-4 as a Surrogate for Enfortumab Vedotin Resistance

被引：13

作者：

Aggen, David H. ^{[1
]}

Chu, Carissa E. ^{[2
]}

Rosenberg, Jonathan E. ^{[1
,3
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Med, Genitourinary Oncol Serv, New York, NY 10065 USA

[2] Mem Sloan Kettering Canc Ctr, Dept Surg, Urol Serv, New York, NY USA

[3] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10065 USA

来源：

CLINICAL CANCER RESEARCH | 2023年 / 29卷 / 08期

关键词：

UROTHELIAL CANCER; AGENT;

D O I：

10.1158/1078-0432.CCR-22-3882

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Clinical data with enfortumab vedotin (EV) suggest that most bladder cancers overexpress NECTIN-4. A recent article shows that NECTIN-4 membranous expression changes with progression to metastatic disease and that low NECTIN-4 expression in metastatic biopsies is potentially associated with EV resistance. These data argue for incorporation of NECTIN-4 expression into future biomarker strategies.

引用

页码：1377 / 1380

页数：4

共 19 条

[1] Biomarkers for immunotherapy in bladder cancer: a moving target [J].

Aggen, David H. ;

Drake, Charles G. .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5

[2] Mutations in PVRL4, Encoding Cell Adhesion Molecule Nectin-4, Cause Ectodermal Dysplasia-Syndactyly Syndrome [J].

Brancati, Francesco ;

Fortugno, Paola ;

Bottillo, Irene ;

Lopez, Marc ;

Josselin, Emmanuelle ;

Boudghene-Stambouli, Omar ;

Agolini, Emanuele ;

Bernardini, Laura ;

Bellacchio, Emanuele ;

Iannicelli, Miriam ;

Rossi, Alfredo ;

Dib-Lachachi, Amina ;

Stuppia, Liborio ;

Palka, Giandomenico ;

Mundlos, Stefan ;

Stricker, Sigmar ;

Kornak, Uwe ;

Zambruno, Giovanna ;

Dallapiccola, Bruno .

AMERICAN JOURNAL OF HUMAN GENETICS, 2010, 87 (02) :265-273

[3] Overcoming Resistance to Anti-Nectin-4 Antibody-Drug Conjugate [J].

Cabaud, Olivier ;

Berger, Ludovic ;

Crompot, Emerence ;

Adelaide, Jose ;

Finetti, Pascal ;

Garnier, Severine ;

Guille, Arnaud ;

Carbuccia, Nadine ;

Farina, Anne ;

Agavnian, Emilie ;

Chaffanet, Max ;

Goncalves, Anthony ;

Charafe-Jauffret, Emmanuelle ;

Mamessier, Emilie ;

Birnbaum, Daniel ;

Bertucci, Francois ;

Lopez, Marc .

MOLECULAR CANCER THERAPEUTICS, 2022, 21 (07) :1227-1235

[4] Preclinical Evaluation of an Anti-Nectin-4 ImmunoPET Reagent in Tumor-Bearing Mice and Biodistribution Studies in Cynomolgus Monkeys [J].

Campbell, Dean O. ;

Noda, Akihiro ;

Verlinsky, Alla ;

Snyder, Josh ;

Fujita, Yuji ;

Murakami, Yoshihiro ;

Fushiki, Hiroshi ;

Miyoshi, Sosuke ;

Lacayo, Sergio ;

Cabral, Edward ;

Yang, Peng ;

Stover, David R. ;

Joseph, Ingrid B. J. K. .

MOLECULAR IMAGING AND BIOLOGY, 2016, 18 (05) :768-775

[5] Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models [J].

Challita-Eid, Pia M. ;

Satpayev, Daulet ;

Yang, Peng ;

An, Zili ;

Morrison, Karen ;

Shostak, Yuriy ;

Raitano, Arthur ;

Nadell, Rossana ;

Liu, Wendy ;

Lortie, Dawn Ratay ;

Capo, Linnette ;

Verlinsky, Alla ;

Leavitt, Monica ;

Malik, Faisal ;

Avina, Hector ;

Guevara, Claudia I. ;

Dinh, Nick ;

Karki, Sher ;

Anand, Banmeet S. ;

Pereira, Daniel S. ;

Joseph, Ingrid B. J. ;

Donate, Fernando ;

Morrison, Kendall ;

Stover, David R. .

CANCER RESEARCH, 2016, 76 (10) :3003-3013

[6] Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin [J].

Chu, Carissa E. ;

Sjostrom, Martin ;

Egusa, Emily A. ;

Gibb, Ewan A. ;

Badura, Michelle L. ;

Zhu, Jun ;

Koshkin, Vadim S. ;

Stohr, Bradley A. ;

Meng, Maxwell, V ;

Pruthi, Raj S. ;

Friedlander, Terence W. ;

Lotan, Yair ;

Black, Peter C. ;

Porten, Sima P. ;

Feng, Felix Y. ;

Chou, Jonathan .

CLINICAL CANCER RESEARCH, 2021, 27 (18) :5123-5130

[7] Genomic heterogeneity as a barrier to precision oncology in urothelial cancer [J].

Clinton, Timothy N. ;

Chen, Ziyu ;

Wise, Hannah ;

Lenis, Andrew T. ;

Chavan, Shweta ;

Donoghue, Mark T. A. ;

Almassi, Nima ;

Chu, Carissa E. ;

Dason, Shawn ;

Rao, Pavitra ;

Rodrigues, James A. ;

Vasani, Naresh B. ;

Ridouani, Fourat ;

Rosenberg, Jonathan E. ;

Bajorin, Dean F. ;

Teo, Min Yuen ;

Bochner, Bernard H. ;

Berger, Michael F. ;

Ostrovnaya, Irina ;

Pietzak, Eugene J. ;

Iyer, Gopa ;

Gao, Sizhi Paul ;

Hu, Wenhuo ;

Al-Ahmadie, Hikmat A. ;

Solit, David B. .

CELL REPORTS, 2022, 41 (12)

[8] Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer [J].

Coates, James T. ;

Sun, Sheng ;

Leshchiner, Ignaty ;

Thimmiah, Nayana ;

Martin, Elizabeth E. ;

McLoughlin, Daniel ;

Danysh, Brian P. ;

Slowik, Kara ;

Jacobs, Raquel A. ;

Rhrissorrakrai, Kahn ;

Utro, Filippo ;

Levovitz, Chaya ;

Denault, Elyssa ;

Walmsley, Charlotte S. ;

Kambadakone, Avinash ;

Stone, James R. ;

Isakoff, Steven J. ;

Parida, Laxmi ;

Juric, Dejan ;

Getz, Gad ;

Bardia, Aditya ;

Ellisen, Leif W. .

CANCER DISCOVERY, 2021, 11 (10) :2436-2445

[9] New and topics: enfortumab vedotin mechanisms of response and resistance in urothelial cancer - What do we understand so far? [J].

Hoffman-Censits, Jean ;

Lombardo, Kara ;

McConkey, David ;

Hahn, Noah M. ;

Bashir, Babar ;

Kelly, Wm Kevin ;

Johnson, Burles ;

Matoso, Andres .

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2021, 39 (10) :619-622

[10] Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer [J].

Hoimes, Christopher J. ;

Flaig, Thomas W. ;

Milowsky, Matthew, I ;

Friedlander, Terence W. ;

Bilen, Mehmet Asim ;

Gupta, Shilpa ;

Srinivas, Sandy ;

Merchan, Jaime R. ;

McKay, Rana R. ;

Petrylak, Daniel P. ;

Sasse, Carolyn ;

Moreno, Blanca Homet ;

Yu, Yao ;

Carret, Anne-Sophie ;

Rosenberg, Jonathan E. .

JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (01) :22-+

← 1 2 →